These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10722138)

  • 21. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA; Sutter RW; Strebel PM; Hadler SC
    JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WHO policy statement on polio vaccines.
    Wkly Epidemiol Rec; 1995 Dec; 70(49):346-7. PubMed ID: 8652353
    [No Abstract]   [Full Text] [Related]  

  • 25. Polio endgame. The exit strategy.
    Roberts L
    Science; 2004 Mar; 303(5666):1969-71. PubMed ID: 15044782
    [No Abstract]   [Full Text] [Related]  

  • 26. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries.
    Wkly Epidemiol Rec; 2003 Jul; 78(28):241-50. PubMed ID: 15571166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Poliomyelitis prevention. Immunization Practices Advisory Committee Centers for Disease Control.
    Ann Intern Med; 1982 May; 96(5):630-4. PubMed ID: 6280539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Need for polio boosters after age two years.
    Rennels MB
    Vaccine; 2009 Jan; 27(2):179-80. PubMed ID: 19007837
    [No Abstract]   [Full Text] [Related]  

  • 30. Change offers children the best of both polio vaccines. Oklahoma State Department of Health and the Centers for Disease Control and Prevention.
    J Okla State Med Assoc; 1997 Apr; 90(4):142-9. PubMed ID: 9143160
    [No Abstract]   [Full Text] [Related]  

  • 31. Poliomyelitis in the United States: the final chapter?
    Modlin JF
    JAMA; 2004 Oct; 292(14):1749-51. PubMed ID: 15479943
    [No Abstract]   [Full Text] [Related]  

  • 32. Experience of vaccination with inactivated poliomyelitis vaccines in Iceland.
    Gudnadóttir M
    Dev Biol Stand; 1981; 47():257-9. PubMed ID: 7227654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivated poliovirus vaccine and vaccine-associated paralytic poliomyelitis.
    Brown B
    JAMA; 1997 Jan 22-29; 277(4):295. PubMed ID: 9002483
    [No Abstract]   [Full Text] [Related]  

  • 34. Change from oral poliovirus vaccine to inactivated poliovirus vaccine.
    Mele A; Jefferson T; Franco E; Salmaso S
    Lancet; 2002 Oct; 360(9340):1178. PubMed ID: 12387987
    [No Abstract]   [Full Text] [Related]  

  • 35. Polio endgame: the global introduction of inactivated polio vaccine.
    Patel M; Zipursky S; Orenstein W; Garon J; Zaffran M
    Expert Rev Vaccines; 2015 May; 14(5):749-62. PubMed ID: 25597843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oral vaccines against poliomyelitis and vaccination-related paralytic poliomyelitis in Germany. Do we need a new immunization strategy?].
    Fescharek R; Arras-Reiter C; Arens ER; Quast U; Maass G
    Wien Med Wochenschr; 1997; 147(19-20):456-61. PubMed ID: 9471843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From the Centers for Disease Control and Prevention. Paralytic poliomyelitis--United States, 1980-1994.
    JAMA; 1997 Feb; 277(7):525-6. PubMed ID: 9032147
    [No Abstract]   [Full Text] [Related]  

  • 40. Poliomyelitis prevention: recommendations for use of inactivated poliovirus vaccine and live oral poliovirus vaccine. American Academy of Pediatrics Committee on Infectious Diseases.
    Pediatrics; 1997 Feb; 99(2):300-5. PubMed ID: 9024465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.